Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Rebecca Shields

Ophthalmology New York, NY Medical Doctor

NPI 1811267255 CMS profile 2779725

1497 3Rd Ave, Apt 3C, New York, NY 10028

Open in the dashboard

General payments

$4,680

123 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Rebecca Shields of New York, NY is reported in the CMS Open Payments database as having received $4,680 across 123 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 79th percentile of Ophthalmology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $635 24
2024 General $421 18
2023 General $1,118 20
2022 General $97 5
2021 General $1,570 21
2020 General $132 8
2019 General $707 27

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Rebecca Shields
  • Ophthalmology median
  • Middle half of Ophthalmology
  • National median

In program year 2025, general payments to Rebecca Shields were reported at $635. Among 13,034 Ophthalmology profiles paid that year, the median was $384 and the middle half received between $136 and $917.

Show as a table
Year Rebecca Shields Ophthalmology median Middle half National median
2019 $707 $258 $104–$655 $163
2020 $132 $126 $45–$321 $114
2021 $1,570 $205 $76–$534 $132
2022 $97 $266 $100–$678 $149
2023 $1,118 $308 $117–$745 $160
2024 $421 $340 $127–$846 $164
2025 $635 $384 $136–$917 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Allergan Inc. $1,556 24 payments
  2. New World Medical,Inc. $807 5 payments
  3. AbbVie, Inc. $717 34 payments
  4. Novartis Pharmaceuticals Corporation $351 21 payments
  5. Aerie Pharmaceuticals, Inc. $254 5 payments
  6. Glaukos Corporation $229 3 payments
  7. Harrow Eye, LLC $137 4 payments
  8. Ocular Therapeutix, Inc. $122 7 payments
  9. Sun Pharmaceutical Industries Inc. $94 5 payments
  10. Alcon Vision LLC $84 4 payments
  11. Other $329 11 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,580 122 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $1,100 1 payment
Products named General payments · program years 2019–2025
  1. ALPHAGAN P $1,100 1 payment
  2. XEN GLAUCOMA TREATMENT SYSTEM Eye Care $345 12 payments
  3. DURYSTA $252 16 payments
  4. XEN GLAUCOMA TREATMENT SYSTEM Glaucoma $250 10 payments
  5. TRAVATAN Z $216 13 payments
  6. Ahmed Glaucoma Valve $142 3 payments
  7. Kahook Dual Blade $142 3 payments
  8. Rhopressa $137 3 payments
  9. DEXTENZA $122 7 payments
  10. rocklatan $117 2 payments
  11. Other $1,773 70 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 24 drugs

Part D claims

1,777

Median for Ophthalmology: 891

Drug cost

$233,916

Median for Ophthalmology: $68,233

Branded share of claims

40.5%

Median for Ophthalmology: 29.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Restasis Cyclosporine Brand 47 $47,964
Lumigan Bimatoprost Brand 73 $35,745
Rhopressa Netarsudil Mesylate Brand 63 $27,222
Rocklatan Netarsudil Mesylat/Latanoprost Brand 35 $23,259
Vyzulta Latanoprostene Bunod Brand 26 $14,559
Combigan Brimonidine Tartrate/Timolol Brand 22 $13,358
Alphagan P Brimonidine Tartrate Brand 38 $9,576
Miebo Perfluorohexyloctane/Pf Brand 13 $9,572
Timolol Maleate Generic 319 $8,599
Simbrinza Brinzolamide/Brimonidine Tart Brand 23 $6,675

The 10 drugs with the highest cost, of 24 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,260 Part D prescribers listed as Ophthalmology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 41 billing codes

Paid by Medicare

$394,892

Medicare's payments for the services billed

Medicare patients

711

Average age 78

Services billed

4,334

429 women, 282 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 65%
Arthritis 44%
Cancer 21%
Osteoporosis 21%
Diabetes 20%
Ischemic heart disease 20%
Atrial fibrillation 18%
Depression 14%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 6 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DURYSTA
  • AbbVie, Inc. $145
$145 — —
DEXTENZA
  • Ocular Therapeutix, Inc. $52
$52 — —
XDEMVY
  • Tarsus Pharmaceuticals, Inc. $25
$25 — —
LUMIGAN
  • AbbVie, Inc. $24
$24 73 —
Rocklatan
  • Alcon Vision LLC $24
$24 35 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 6 in the dashboard with a free account

Records

123 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Ophthalmology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record